Phreesia Future Growth

Future criteria checks 1/6

Phreesia is forecast to grow earnings and revenue by 72% and 11.9% per annum respectively. EPS is expected to grow by 73.2% per annum. Return on equity is forecast to be -13.9% in 3 years.

Key information

72.0%

Earnings growth rate

73.2%

EPS growth rate

Healthcare Services earnings growth28.1%
Revenue growth rate11.9%
Future return on equity-13.9%
Analyst coverage

Good

Last updated18 Oct 2024

Recent future growth updates

Here's What Analysts Are Forecasting For Phreesia, Inc. (NYSE:PHR) After Its Second-Quarter Results

Sep 06
Here's What Analysts Are Forecasting For Phreesia, Inc. (NYSE:PHR) After Its Second-Quarter Results

Recent updates

Market Participants Recognise Phreesia, Inc.'s (NYSE:PHR) Revenues

Nov 07
Market Participants Recognise Phreesia, Inc.'s (NYSE:PHR) Revenues

Is Phreesia (NYSE:PHR) Weighed On By Its Debt Load?

Oct 08
Is Phreesia (NYSE:PHR) Weighed On By Its Debt Load?

Here's What Analysts Are Forecasting For Phreesia, Inc. (NYSE:PHR) After Its Second-Quarter Results

Sep 06
Here's What Analysts Are Forecasting For Phreesia, Inc. (NYSE:PHR) After Its Second-Quarter Results

Phreesia: Remain Bullish Given The Healthy Growth Outlook

Sep 05

Market Participants Recognise Phreesia, Inc.'s (NYSE:PHR) Revenues Pushing Shares 26% Higher

Jul 18
Market Participants Recognise Phreesia, Inc.'s (NYSE:PHR) Revenues Pushing Shares 26% Higher

Phreesia: Growth Remains Strong, With EBITDA Margin Set To Improve

Jun 06

The Price Is Right For Phreesia, Inc. (NYSE:PHR)

May 25
The Price Is Right For Phreesia, Inc. (NYSE:PHR)

Are Investors Undervaluing Phreesia, Inc. (NYSE:PHR) By 39%?

May 03
Are Investors Undervaluing Phreesia, Inc. (NYSE:PHR) By 39%?

At US$23.80, Is Phreesia, Inc. (NYSE:PHR) Worth Looking At Closely?

Apr 12
At US$23.80, Is Phreesia, Inc. (NYSE:PHR) Worth Looking At Closely?

Phreesia Continues To Stay Positive On The Business Growth

Apr 03

Phreesia: Healthcare Digitization Beneficiary Hampered By Valuation

Mar 01

Investors Still Waiting For A Pull Back In Phreesia, Inc. (NYSE:PHR)

Feb 16
Investors Still Waiting For A Pull Back In Phreesia, Inc. (NYSE:PHR)

Phreesia: Remain Buy Rated As The Business Pivot Towards Profitable Growth

Jan 04

Is Phreesia Finally Turning The Corner?

Dec 07

Does Phreesia (NYSE:PHR) Have A Healthy Balance Sheet?

Oct 25
Does Phreesia (NYSE:PHR) Have A Healthy Balance Sheet?

Phreesia: Share Price Dip Is A Buying Opportunity

Sep 21

Phreesia: Strong Execution Should Continue To Drive Growth

Jul 11

Phreesia, Inc.'s (NYSE:PHR) Share Price Matching Investor Opinion

May 18
Phreesia, Inc.'s (NYSE:PHR) Share Price Matching Investor Opinion

Phreesia: Strong Growth Momentum With Expanded TAM

Jan 28

Phreesia - Healthcare Ecosystem At An Attractive Valuation

Dec 13

Phreesia Q3 2023 Earnings Preview

Dec 07

Phreesia GAAP EPS of -$0.89 beats by $0.08, revenue of $67.9M beats by $2.15M

Sep 07

Phreesia: Their Time Has Passed

May 10

Opportunistic Time To Buy Phreesia's Healthcare Disruption

Dec 27

Earnings and Revenue Growth Forecasts

NYSE:PHR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
1/31/2027545-877868
1/31/2026481-39375715
1/31/2025419-6822815
7/31/2024390-100-251N/A
4/30/2024374-119-44-19N/A
1/31/2024356-137-57-32N/A
10/31/2023338-144-69-45N/A
7/31/2023319-152-85-60N/A
4/30/2023301-162-95-70N/A
1/31/2023281-176-116-90N/A
10/31/2022262-185-138-112N/A
7/31/2022245-181-150-116N/A
4/30/2022228-158-134-103N/A
1/31/2022213-118-106-75N/A
10/31/2021197-80-65-33N/A
7/31/2021180-50-30-9N/A
4/30/2021164-32-27-4N/A
1/31/2021149-27-163N/A
10/31/2020140-23-140N/A
7/31/2020134-19-16-2N/A
4/30/2020130-83-121N/A
1/31/2020125-91-111N/A
10/31/2019118-102-16-4N/A
7/31/2019110-113-110N/A
4/30/2019104-54-101N/A
1/31/2019100-45-12-2N/A
1/31/201880-38N/A-11N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PHR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PHR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PHR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PHR's revenue (11.9% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: PHR's revenue (11.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PHR is forecast to be unprofitable in 3 years.


Discover growth companies